Inclusion Body Myositis Treated with Alemtuzumab

  • Juliana Sá Centro Hospitalar Cova da Beira, Covilhã, Portugal
  • João Costelha nidade Local de Saúde do Alto Minho, EPE, Portugal
  • Antonio Marinho Centro Hospitalar do Porto, Porto, Portugal

Keywords

Inclusion body myositis, alemtuzumab, myopathy, treatment

Abstract

Inclusion body myositis (IBM) is a chronic inflammatory myopathy with a progressive course. It is more common in the later years of life and usually presents with limb weakness. We present the case of a patient who developed proximal weakness in the lower limbs and, four years later, facial asymmetry. Blood analysis revealed high lactate dehydrogenase and creatinine kinase values. The diagnosis was obtained through muscle biopsy which met the histological criteria for IBM. The patient started treatment with alemtuzumab, leading to stabilisation of the symptoms in two years.

VIEW THE ENTIRE ARTICLE

References

  • Lam L, Scheper S, Zagorski N, Chung M, Noguchi H, Liow KK. Inclusion body myositis: a case of bilateral extremity weakness. >Hawaii J Med Public Health 2013;72417–420.

  • Suwa Y, Suzuki N, Soga T, et al. Sporadic inclusion body myositis manifesting as isolated muscle weakness of the finger flexors three years after disease onset. Intern Med 2016;55:3521–3524.

  • Schmit K, Kleinschinitz K, Rakocevi G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurology 2016;16:48.

  • Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009;132:1536-1544.
  • Published: 2019-12-12

    Issue: Vol 6 No 12 (view)

    Section: Articles

    How to cite:
    Sá, J., Costelha, J., & Marinho, A. (2019). Inclusion Body Myositis Treated with Alemtuzumab. European Journal of Case Reports in Internal Medicine, 6(12). https://doi.org/https://doi.org/10.12890/2019_001368